Amendment: SEC Form 10-Q/A filed by Repligen Corporation
$RGEN
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Get the next $RGEN alert in real time by email
Chat with this insight
Save time and jump to the most important pieces.
Recent Analyst Ratings for $RGEN
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/18/2025 | $155.00 | In-line | Evercore ISI |
| 2/10/2025 | $200.00 | Buy | TD Cowen |
| 12/17/2024 | $165.00 | Hold | Canaccord Genuity |
| 11/14/2024 | Peer Perform | Wolfe Research | |
| 8/28/2024 | $180.00 | Overweight | Wells Fargo |
| 6/26/2024 | $180.00 → $155.00 | Hold → Buy | Deutsche Bank |
| 6/18/2024 | Neutral | Guggenheim | |
| 12/4/2023 | Buy → Hold | The Benchmark Company |
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (NASDAQ:MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for vital health and safety applications. The addition of these desktop assets complements and strengthens Repligen's differentiated PAT portfolio that provides its bioph
Repligen Reports Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter revenue of $168 million and full year revenue of $634 millionFourth quarter orders and revenues sequentially increased 11% and 8% respectivelyOrders outpaced revenue by 6% in the fourth quarter Provides full year 2025 guidance of 8% to 12% reported growth and 10% to 14% excluding COVID-related revenue WALTHAM, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2024, covering the three- and twelve-month periods ended December 31, 2024. The company is also providing financial guidance for the full year 2025. Olivier
Repligen to Report Fourth Quarter and Full Year 2024 Financial Results
WALTHAM, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2024 financial results on Thursday, February 20, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2024. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations se
Evercore ISI initiated coverage on Repligen with a new price target
Evercore ISI initiated coverage of Repligen with a rating of In-line and set a new price target of $155.00
TD Cowen initiated coverage on Repligen with a new price target
TD Cowen initiated coverage of Repligen with a rating of Buy and set a new price target of $200.00
Canaccord Genuity initiated coverage on Repligen with a new price target
Canaccord Genuity initiated coverage of Repligen with a rating of Hold and set a new price target of $165.00
Director Pax Margaret bought $37,672 worth of shares (250 units at $150.69), increasing direct ownership by 32% to 1,043 units (SEC Form 4)
4 - REPLIGEN CORP (0000730272) (Issuer)
Director Madaus Martin D bought $201,776 worth of shares (1,615 units at $124.94) (SEC Form 4)
4 - REPLIGEN CORP (0000730272) (Issuer)
Director Barthelemy Nicolas bought $150,540 worth of shares (1,200 units at $125.45), increasing direct ownership by 35% to 4,668 units (SEC Form 4)
4 - REPLIGEN CORP (0000730272) (Issuer)
Chief Operating Officer Bylund James was granted 381 shares and covered exercise/tax liability with 175 shares, increasing direct ownership by 0.86% to 24,165 units (SEC Form 4)
4 - REPLIGEN CORP (0000730272) (Issuer)
Director Hunt Anthony sold $4,080,663 worth of shares (26,756 units at $152.51) and exercised 26,756 shares at a strike of $54.73 (SEC Form 4)
4 - REPLIGEN CORP (0000730272) (Issuer)
Director Pax Margaret bought $37,672 worth of shares (250 units at $150.69), increasing direct ownership by 32% to 1,043 units (SEC Form 4)
4 - REPLIGEN CORP (0000730272) (Issuer)
SEC Form PRE 14A filed by Repligen Corporation
PRE 14A - REPLIGEN CORP (0000730272) (Filer)
SEC Form 10-K filed by Repligen Corporation
10-K - REPLIGEN CORP (0000730272) (Filer)
SEC Form NT 10-K filed by Repligen Corporation
NT 10-K - REPLIGEN CORP (0000730272) (Filer)
BioLife Solutions Appoints Tony J. Hunt to its Board of Directors
BOTHELL, Wash., Dec. 16, 2024 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of bioproduction tools and services for the cell and gene therapy (CGT) market, announces the appointment of Tony J. Hunt, Executive Chairman of Repligen Corporation (NASDAQ:RGEN) and a recognized leader in bioprocessing innovation, to its board of directors effective January 2, 2025. His appointment increases board membership to six. "Tony is highly respected in the life sciences industry with decades of accomplishments, and it is
Repligen Announces CEO Transition Plan
WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that its Board of Directors ("Board") has approved the planned transition of Tony J. Hunt from Chief Executive Officer ("CEO") to Executive Chair, effective September 1, 2024. The Company's Board has appointed Olivier Loeillot to succeed Mr. Hunt in the role of President and CEO, also effective September 1, 2024. At the same time, Mr. Loeillot, who joined the Company in October 2023 as President and Chief Commercial Officer, will join the Repligen Board, while current Board Chair Karen A. Dawes will assume the role of
Repligen Appoints Maggie A. Pax to Board of Directors
WALTHAM, Mass., March 19, 2024 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced the appointment to its Board of Directors of life sciences industry executive Maggie A. Pax. This appointment expands the size of Repligen's board from eight to nine members. Ms. Pax brings to Repligen over 25 years of experience leading the development and execution of growth strategies for global companies. This includes eight years with Thermo Fisher Scientific, where, from 2016–2020, she served as Vice President, Strategy and Innovation for the clinical supply chain business. In this role, she led strategic planning, developed customer-facing innovation programs, and drove the business
Repligen Purchases Bioprocessing Analytics Portfolio from 908 Devices
WALTHAM, Mass. and BOSTON, March 04, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, and 908 Devices Inc. (NASDAQ:MASS), a pioneer in purpose-built handheld and desktop devices for chemical analysis, announce that Repligen has purchased 908 Devices' desktop portfolio of four devices for bioprocessing process analytical technology (PAT) applications. 908 Devices remains focused on the growth of its newly expanded handheld device portfolio for vital health and safety applications. The addition of these desktop assets complements and strengthens Repligen's differentiated PAT portfolio that provides its bioph
Repligen Reports Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter revenue of $168 million and full year revenue of $634 millionFourth quarter orders and revenues sequentially increased 11% and 8% respectivelyOrders outpaced revenue by 6% in the fourth quarter Provides full year 2025 guidance of 8% to 12% reported growth and 10% to 14% excluding COVID-related revenue WALTHAM, Mass., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its fourth quarter of 2024, covering the three- and twelve-month periods ended December 31, 2024. The company is also providing financial guidance for the full year 2025. Olivier
Repligen to Report Fourth Quarter and Full Year 2024 Financial Results
WALTHAM, Mass., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report its fourth quarter 2024 financial results on Thursday, February 20, 2025. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. ET to discuss business updates and financial results for the three- and twelve- month reporting periods ended December 31, 2024. The conference call will be accessible by dialing toll-free (844) 274-3999 for domestic callers and (412) 317-5607 for international callers. No passcode is required for the live call. In addition, a webcast will be accessible via the Investor Relations se
Amendment: SEC Form SC 13G/A filed by Repligen Corporation
SC 13G/A - REPLIGEN CORP (0000730272) (Subject)
Amendment: SEC Form SC 13G/A filed by Repligen Corporation
SC 13G/A - REPLIGEN CORP (0000730272) (Subject)
SEC Form SC 13G/A filed by Repligen Corporation (Amendment)
SC 13G/A - REPLIGEN CORP (0000730272) (Subject)